SR One

SR One employs a back-and-build venture capital model targeting biotechnology companies across development stages from seed to late stage. The firm focuses on novel scientific approaches with clear therapeutic pathways, spanning multiple modalities and indications. Investments range from preclinical startups to public clinical-stage companies.

SR One maintains a transatlantic footprint with offices in Redwood City, California, and London, UK. The firm sources opportunities across the US West Coast and European biotech ecosystems. This dual-hub structure is designed to provide portfolio companies with regional expertise and access to capital on both sides of the Atlantic.

The firm invests across a broad range of therapeutic areas, including oncology, immunology, cardiometabolic disease, CNS disorders, rare diseases, infectious disease, renal conditions, neuropsychiatry, hematology, and rheumatology. This multi-indication scope reflects a platform-agnostic approach to drug development.

SR One is a biotechnology venture capital firm, not a family office. It operates as an independent asset manager, though its lineage traces back to the corporate venture arm of GSK. The team transitioned from that legacy structure and now manages third-party capital through a traditional VC fund model.

The SR One team originally functioned within GSK as a corporate venture group. Certain portfolio investments listed on the firm's website were made during that legacy period and are not held in the current independent funds. The firm now operates independently from GSK, managing its own fund vehicles.